Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia

BACKGROUND:

Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical improvement in rhuEPO treated patients with Friedreich ataxia (FRDA).

Read More: A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Event A.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News